Clinical Trial Update: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating a triple combination of tremelimumab, durvalumab, and belinostat in urothelial carcinoma; the study is currently active but not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Belinostat (belinostat)
• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: University of Utah | Conditions: Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING